Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D (RESPOND-CAS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02374801|
Recruitment Status : Active, not recruiting
First Posted : March 2, 2015
Last Update Posted : January 11, 2019
|Condition or disease||Intervention/treatment||Phase|
|Heart Failure (NYHA Class III and Ambulatory IV)||Device: SonR automatic optimization feature turned ON ("AV+VV").||Not Applicable|
Since the introduction of cardiac resynchronization therapy (CRT) on a large scale, it has been observed that approximately 30% of recipient patients are non-responsive to therapy. This non-responsiveness can be decreased by optimizing the device programming, particularly the stimulation rate, paced and sensed atrioventricular (AV) delay, and the interventricular (VV) delay.
All CRT patients need a 100% rate of ventricular capture, but beyond this the achievement of therapy effectiveness requires the identification of the optimal pacing configuration, which varies among patients. The optimization of CRT systems, usually based on ultrasound imaging is time-consuming and the number of patients in need of multiple optimization procedures due to ventricular remodeling is growing rapidly.
The mechanical effects of a more coordinated contraction result in a shortening of the isovolumetric contraction phase and the pre-ejection time, and an increase in LV dP/dt (change in left ventricular pressure over time. The concept of measuring contractility with an implantable accelerometer was first clinically validated through a multicenter study on a rate responsive pacing system (BEST - Living from SORIN Biomedica) in 1996. This study positively demonstrates that measurement of Peak Endocardial Acceleration signal (called PEA or SonR) is feasible and reliable in the long-term, both for the purpose of rate response and as a hemodynamic monitor of cardiac function.
More recent clinical studies have demonstrated that optimal VV and AV Delays determined using algorithms based on SonR signal analysis (SonR method) are correlated with the highest hemodynamic improvement and lead to significant clinical benefit for the patients, thus reducing the rate of non-responsiveness to CRT therapy.
Therefore, frequent and automatic AV and VV delay optimization in patients with CRT-D devices could benefit both patients, through increasing the percent of CRT responders, and clinicians, through simplifying CRT optimization.
The inclusion phase of the "Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the PARADYM RF SonR CRT-D" (RESPOND CRT Study, code ITSY06) has been completed. A total of 1039 patients have been enrolled in 125 centers in Europe, Australia and USA, from 13 January 2012 to 14 October 2014.
Safety has been monitored continuously throughout the RESPOND-CRT trial by the Data Safety Monitoring Board (DSMB). The DSMB charter is to provide recommendations to the Sponsor to suspend or stop the study if there is clear evidence of harm or harmful side-effects related to the use of the device or study procedures. To date, there have been no safety concerns raised by the RESPOND-CRT study data and the DSMB has recommended continuation of the clinical study.
Additionally, safety is supported by the European marketing history. As the SonR System is CE marked, RESPONDCRT is being conducted as a post-market study in Europe. Therefore in addition to the 1000+ patients enrolled in the RESPOND-CRT IDE, an additional 3000+ patients have received the SonR system outside the study.
As a supplement to the RESPOND CRT IDE Study a Continued Access Study (CAS) is being conducted according to the potential public health need and preliminary evidence that the device is likely to be effective with no significant safety concerns for the proposed indication.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||49 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Continued Access Clinical Trial of the SonRtip Lead and Automatic AV-VV Optimization Algorithm in the Paradym RF SonR CRT-D|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||April 2019|
|Estimated Study Completion Date :||December 2019|
This is a single-arm trial. All patients will be implanted with the PARADYM RF SONR CRT-D device and the SonRtip bipolar atrial lead. After successful implant, all patients will be programmed with the SonR automatic optimization feature turned ON ("AV+VV").
Device: SonR automatic optimization feature turned ON ("AV+VV").
- Acute SonRtip Lead Complication-Free Rate [ Time Frame: Month 3 ]All patients implanted with the SonRtip lead
- Chronic SonRtip Lead Complication-Free Rate [ Time Frame: From month 3 to month 12 ]All patients implanted with the SonRtip lead
- SonRtip Lead, pacing threshold [ Time Frame: 12 months ]All patients implanted with the SonRtip lead
- SonRtip Lead, sensing amplitude [ Time Frame: 12 months ]All patients implanted with the SonRtip lead
- SonRtip Lead, pacing impedance [ Time Frame: 12 months ]All patients implanted with the SonRtip lead
- Report deaths from any cause [ Time Frame: 12 months ]All patients enrolled
- Report HF-related events [ Time Frame: 12 months ]All patients implanted with the entire system
- Report Quality of Life improvement [ Time Frame: 12 months ]All patients implanted with the entire system
- Report NYHA class improvement [ Time Frame: 12 months ]All patients implanted with the entire system
- Report echocardiographic parameters trend [ Time Frame: Month 12 ]All patients implanted with the entire system
- Report Adverse Events [ Time Frame: 12 months ]All patients enrolled
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02374801
|United States, Ohio|
|University Hospitals of Cleveland|
|Cleveland, Ohio, United States, 44106|
|Principal Investigator:||Jagmeet P. Singh, M.D.||Massachusetts General Hospital|